Business Overview: Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

---

Executive Summary

Alnylam Pharmaceuticals, Inc. is the pioneering leader in RNA interference (RNAi) therapeutics, a Nobel-Prize-winning scientific mechanism that allows drugs to silence disease-causing genes at the RNA level before they can produce harmful proteins. Alnylam has translated this platform into multiple approved medicines, including Onpattro (patisiran) and Amvuttra (vutrisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis, Givlaari (givosiran) for acute hepatic porphyria, and Oxlumo (lumasiran) for primary hyperoxaluria type 1 — rare, often severe genetic diseases with historically limited treatment options.

Headquartered in Cambridge, Massachusetts, Alnylam also earns royalty revenue from Leqvio (inclisiran), a cholesterol-lowering RNAi therapy it discovered and licensed to Novartis, which has become one of the most closely watched new products in cardiovascular medicine. Alnylam's broader pipeline continues to apply its RNAi platform across additional rare disease, cardiometabolic, and other therapeutic areas.

---

1. Core Business Model & How They Work

Alnylam discovers and develops RNAi therapeutics — synthetic small interfering RNA (siRNA) molecules designed to silence specific disease-causing genes — commercializing approved products directly in rare and genetic diseases while also licensing certain RNAi assets (such as Leqvio) to larger pharmaceutical partners for broader commercialization in larger markets like cardiovascular disease.

[ RNAi Platform & Gene Target Discovery ] ➡️ [ Clinical Development Across Rare/Genetic & Cardiometabolic Diseases ] ➡️ [ FDA/EMA Approval ] ➡️ [ Direct Commercialization (Rare Disease) OR Partnered Commercialization (Leqvio via Novartis) ] ➡️ [ Product Sales + Royalty Revenue ]

Key Operational Drivers

1. First-Mover RNAi Platform Leadership: Alnylam pioneered RNAi therapeutics and holds an extensive, foundational patent estate covering core RNAi chemistry and delivery technology, providing a significant scientific and intellectual property moat in this therapeutic modality.
2. Multi-Product Rare Disease Commercial Portfolio: Onpattro, Amvuttra, Givlaari, and Oxlumo together give Alnylam a diversified, directly commercialized rare-disease product portfolio, reducing dependence on any single product.
3. High-Value Royalty Stream from Leqvio: The Novartis partnership on Leqvio provides Alnylam with royalty income from a cardiovascular product addressing a vastly larger patient population than its rare-disease portfolio alone, without requiring Alnylam to build a large primary-care commercial infrastructure.
4. GalNAc Conjugate Delivery Technology: Alnylam's proprietary subcutaneous delivery technology (enabling infrequent, convenient dosing for many of its products) is a key technical differentiator supporting patient and physician adoption.

---

2. Business Segments

Alnylam operates as a single integrated RNAi therapeutics business, with commercial and pipeline activity organized around:

• TTR-Mediated Amyloidosis Franchise (Onpattro, Amvuttra): RNAi therapies for hereditary transthyretin-mediated amyloidosis, a rare, progressive, and historically fatal genetic disease.
• Acute Hepatic Porphyria (Givlaari): RNAi therapy for a rare genetic disorder causing acute, potentially life-threatening attacks.
• Primary Hyperoxaluria (Oxlumo): RNAi therapy for a rare genetic disease causing progressive kidney damage.
• Cardiometabolic/Leqvio Royalty: Royalty revenue from Novartis's commercialization of Leqvio (inclisiran) for cholesterol management.
• Broader RNAi Pipeline: Additional RNAi candidates across rare disease and other therapeutic areas leveraging the core platform.

---

3. Product Portfolio & Revenue Contributors

---

4. Competitive Landscape

                    High RNAi/Gene-Silencing Technology Focus
                                 │
       Alnylam Pharmaceuticals ● │
                                 │
   Arrowhead Pharmaceuticals ●   │              ● Ionis Pharmaceuticals (antisense)
                                 │
─────────────────────────────────┼─────────────────────────────────
   RNA-Targeted Therapeutics      │              Traditional Small Molecule/Biologic
                                 │
    Pfizer/BridgeBio (TTR amyloidosis, tafamidis) ●│  ● Traditional Biologics/Antibodies
                                 │
                    Low RNAi/Gene-Silencing Technology Focus

Competitors by Domain

TTR Amyloidosis Treatment

• Key Competitors: Pfizer's tafamidis (Vyndaqel/Vyndamax), a non-RNAi oral stabilizer therapy, and BridgeBio Pharma's acoramidis compete for the TTR amyloidosis market, alongside other emerging gene-silencing and gene-editing approaches (including from Intellia Therapeutics).
• Dynamics: Multiple distinct mechanisms (RNAi silencing versus TTR stabilization versus emerging gene editing) now compete in this growing market; Alnylam's Amvuttra offers a differentiated dosing profile versus daily oral tafamidis, but faces genuine mechanism-based competition.

RNAi/Antisense Therapeutics Platform Competition

• Key Competitors: Arrowhead Pharmaceuticals and Ionis Pharmaceuticals both operate RNA-targeted therapeutic platforms (RNAi and antisense oligonucleotide technology, respectively) with their own pipelines and partnership deals.
• Dynamics: As the RNA-therapeutics field has matured, more companies have entered with competing delivery and chemistry platforms, though Alnylam's first-mover patent estate and multiple approved products provide meaningful competitive advantage.

---

5. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Pioneering RNAi patent estate: Alnylam holds a foundational and extensive intellectual property portfolio covering core RNAi chemistry, delivery, and manufacturing, built over more than two decades as the field's scientific pioneer.
• Multiple approved, commercially validated products: A rare achievement among biotech platform companies — Alnylam has successfully converted its core science into four approved rare-disease products plus a major partnered cardiovascular product.
• High-value Novartis partnership on Leqvio: Provides diversified, high-margin royalty revenue from a large primary-care market without requiring Alnylam to build out its own large-scale commercial infrastructure for that indication.
• Proprietary GalNAc conjugate delivery technology: Enables convenient, infrequent subcutaneous dosing that is a meaningful patient and physician adoption advantage.

Strategic Risks & Vulnerabilities

1. Mechanism-based competition in TTR amyloidosis: Pfizer's tafamidis and other emerging therapies (including potential gene-editing approaches) compete for the same growing TTR amyloidosis market.
   • Mitigation Strategy: Continued clinical data generation supporting Amvuttra's differentiated efficacy and dosing convenience profile.
2. Rare disease market size constraints: Even successful rare-disease products address relatively small patient populations, limiting the ultimate revenue ceiling for several of Alnylam's directly commercialized products absent broader label expansion.
   • Mitigation Strategy: Pipeline expansion into larger-market indications (as demonstrated by the Leqvio cardiovascular partnership).
3. Ongoing R&D and commercial infrastructure investment needs: Sustaining platform leadership requires continued substantial investment in both pipeline development and direct commercial capabilities.
   • Mitigation Strategy: Balancing directly commercialized rare-disease products with partnered, royalty-generating large-market opportunities to manage capital intensity.

---

6. Financial Overview & Performance Matrix

---

7. Summary Conclusion

Alnylam Pharmaceuticals has successfully translated its pioneering RNAi science into a diversified, commercially validated rare-disease product portfolio alongside a highly valuable royalty stream from Novartis's Leqvio in cardiovascular disease — a rare and impressive achievement for a platform biotechnology company. Its foundational patent estate and proprietary delivery technology provide meaningful, durable competitive advantages in the RNAi therapeutic modality.

The company's long-term trajectory depends on defending its TTR amyloidosis franchise against mechanism-based competition from Pfizer's tafamidis and emerging gene-editing approaches, continuing to expand its pipeline into larger-market indications beyond rare disease, and sustaining its position as the leading RNAi platform company as competitors like Arrowhead Pharmaceuticals and Ionis Pharmaceuticals continue advancing their own RNA-therapeutics platforms.